Sera Prognostics (NASDAQ:SERA) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Sera Prognostics (NASDAQ:SERA) announced its quarterly earnings results on Wednesday. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01, FiscalAI reports. Sera Prognostics had a negative return on equity of 41.69% and a negative net margin of 34,343.16%.The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.03 million.

Sera Prognostics Stock Down 5.0%

Shares of Sera Prognostics stock traded down $0.10 on Wednesday, reaching $1.91. The company’s stock had a trading volume of 217,068 shares, compared to its average volume of 59,219. The company has a market capitalization of $73.73 million, a P/E ratio of -2.48 and a beta of 1.01. The stock has a 50-day moving average price of $2.70 and a 200-day moving average price of $3.03. Sera Prognostics has a 52-week low of $1.37 and a 52-week high of $4.20.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on SERA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sera Prognostics in a research note on Monday, December 29th. Jefferies Financial Group raised shares of Sera Prognostics to a “strong-buy” rating in a report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $5.00.

Insider Activity

In related news, CEO Zhenya Lindgardt sold 22,639 shares of Sera Prognostics stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $1.90, for a total value of $43,014.10. Following the sale, the chief executive officer owned 741,287 shares of the company’s stock, valued at approximately $1,408,445.30. This trade represents a 2.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders sold 57,133 shares of company stock worth $115,794. Company insiders own 15.80% of the company’s stock.

Hedge Funds Weigh In On Sera Prognostics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Cetera Investment Advisers acquired a new stake in shares of Sera Prognostics in the fourth quarter valued at about $74,000. Barclays PLC raised its position in shares of Sera Prognostics by 267.4% during the 4th quarter. Barclays PLC now owns 36,722 shares of the company’s stock worth $108,000 after purchasing an additional 26,726 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Sera Prognostics during the 4th quarter worth about $203,000. Lido Advisors LLC purchased a new position in Sera Prognostics in the 3rd quarter valued at about $68,000. Finally, Citadel Advisors LLC boosted its holdings in Sera Prognostics by 1.9% in the 3rd quarter. Citadel Advisors LLC now owns 653,746 shares of the company’s stock worth $2,000,000 after buying an additional 12,439 shares during the last quarter. 54.64% of the stock is owned by hedge funds and other institutional investors.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.